Atorvastatin improves plaque stability in ApoE-knockout mice by regulating chemokines and chemokine receptors

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Nie, Peng ^a   Li, Dandan ^a   Hu, Liuhua ^a   Jin, Shuxuan ^a   Yu, Ying ^a   Cai, Zhaohua ^a   Shao, Qin ^a   Shen, Jieyan ^a   Yi, Jing ^b   Xiao, Hua ^a   Shen, Linghong ^a   He, Ben ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; CHOLESTEROL; COLLAGENASE; COLLAGENASE 3; FRACTALKINE; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL COLLAGENASE; TUMOR NECROSIS FACTOR ALPHA; APOLIPOPROTEIN E; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM; ENZYME ACTIVITY; INHIBITION KINETICS; LIPID STORAGE; MACROPHAGE FUNCTION; MACROPHAGE INFILTRATION; MONOCYTE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; VASCULITIS; ANIMAL; BLOOD; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; PLAQUE, ATHEROSCLEROTIC; TIME;

ANIMALS; APOLIPOPROTEINS E; CHEMOKINES; COLLAGENASES; HEPTANOIC ACIDS; MACROPHAGES; MICE; MICE, KNOCKOUT; MONOCYTES; PLAQUE, ATHEROSCLEROTIC; PYRROLES; RECEPTORS, CHEMOKINE; TIME FACTORS;

EID: 84901236373     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097009     Document Type: Article

References (24)

1. Momi S, Monopoli A, Alberti PF, Falcinelli E, Corazzi T, et al. (2012) Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis. Cardiovasc Res 94: 428-438.
2. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, et al. (2007) Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 117:195-205. (Pubitemid 46048466)
3. Cho KY, Miyoshi H, Kuroda S, Yasuda H, Kamiyama K, et al. (2013) The phenotype of infiltrating macrophages influences arteriosclerotic plaque vulnerability in the carotid artery. J Stroke Cerebrovasc Dis 22:910-918.
4. Shen LH, Zhou L, Wang BY, Pu J, Hu LH, et al. (2008) Oxidized low-density lipoprotein induces differentiation of RAW264.7 murine macrophage cell line into dendritic-like cells. Atherosclerosis 199:257-264.
5. Hu LH, Zhang T, Shao Q, Li DD, Jin SX, et al. (2012) Atorvastatin suppresses oxidized LDL-induced dendritic cell-like differentiation of RAW264.7 cells regulated by the p38 MAPK pathway. Mol Cell Biochem 371:105-113.
6. Bea F, Blessing E, Bennett B, Levitz M, Wallace EP, et al. (2002) Simvastatin Promotes Atherosclerotic Plaque Stability in ApoE-Deficient Mice Independently of Lipid Lowering. Arterioscler Thromb Vasc Biol 22:1832-1837. (Pubitemid 35315769)
7. Chen YC, Bui AV, Diesch J, Manasseh R, Hausding C, et al. (2013) A Novel Mouse Model of Atherosclerotic Plaque Instability for Drug Testing and Mechanistic/Therapeutic Discoveries Using Gene and MicroRNA Expression Profiling. Circ Res 113:252-265.
8. Soehnlein O, Drechsler M, Döring Y, Lievens D, Hartwig H, et al. (2013) Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes. EMBO Mol Med 5:471-481.
9. Naert G, Rivest S (2012) Hematopoietic CC-chemokine receptor 2 (CCR2) competent cells are protective for the cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. Mol Med 18:297-313.
10. Landsman L, Bar-On L, Zernecke A, Kim KW, Krauthgamer R, et al. (2009) CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 113:963-972.
11. Jin SX, Shen LH, Nie P, Yuan W, Hu LH, et al. (2012) Endogenous Renovascular Hypertension Combined With Low Shear Stress Induces Plaque Rupture in Apolipoprotein E-Deficient Mice. Arterioscler Thromb Vasc Biol 32:2372-2379.
12. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S (2002) Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 45:147-154. (Pubitemid 35425654)
13. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, et al. (2001) Statin-induced inhibition of the Rhosignaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 107:1423-1432. (Pubitemid 32522036)
14. Kleemann R, Verschuren L, de Rooij BJ, Jan Lindeman, de Maat MM, et al. (2004) Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 103:4188-4194. (Pubitemid 38685361)
15. Ruiz-Velasco N, Domínguez A, Vega MA (2004) Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-gamma ligands Putative contribution of Rho GTPases in statin-induced CD36 expression. Biochem Pharmacol 67:303-313. (Pubitemid 38112761)
16. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, et al. (2001) Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 103: 993-999. (Pubitemid 32183806)
17. Clark AK, Staniland AA, Malcangio M (2011) Fractalkine/CX3CR1 signalling in chronic pain and inflammation. Curr Pharm Biotechnol 12:1707-1714.
18. van der Valk FM, van Wijk DF, Stroes ES (2012) Novel anti-inflammatory strategies in atherosclerosis. Curr Opin Lipidol 23:532-539.
19. Liu P, Patil S, Rojas M, Fong AM, Smyth SS, et al. (2006) CX3CR1 deficiency confers protection from intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol 26:2056-2062. (Pubitemid 44253788)
20. Liu P, Yu YR, Spencer JA, Johnson AE, Vallanat CT, et al. (2008) CX3CR1 deficiency impairs dendritic cell accumulation in arterial intima and reduces atherosclerotic burden. Arterioscler Thromb Vasc Biol 28:243-250. (Pubitemid 351161195)
21. Liu H, Jiang D (2011) Fractalkine/CX3CR1 and atherosclerosis. Clin Chim Acta 412:1180-1186.
22. White GE, Greaves DR (2012) Fractalkine: a survivor's guide: chemokines as antiapoptotic mediators. Arterioscler Thromb Vasc Biol 32:589-594.
23. Flierl U, Schäfer A (2012) Fractalkine - a local inflammatory marker aggravating platelet activation at the vulnerable plaque. Thromb Haemost 108(3):457-463.
24. Jerath MR, Liu P, Struthers M, Demartino JA, Peng R, et al. (2010) Dual targeting of CCR2 and CX3CR1 in an arterial injury model of vascular inflammation. Thromb J 8:14.